Cargando…

Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling

BACKGROUND: The expression of side-population (SP) cells and their relation to tumour-initiating cells (T-ICs) have been insufficiently studied in breast cancer (BC). We therefore evaluated primary cell cultures derived from patients and a panel of human BC cell lines with luminal- or basal-molecula...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakanishi, T, Chumsri, S, Khakpour, N, Brodie, A H, Leyland-Jones, B, Hamburger, A W, Ross, D D, Burger, A M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2010
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833247/ https://www.ncbi.nlm.nih.gov/pubmed/20145614 http://dx.doi.org/10.1038/sj.bjc.6605553

Ejemplares similares

Bmi1 marks distinct castration-resistant luminal progenitor cells competent for prostate regeneration and tumour initiation
por: Yoo, Young A., et al.
Publicado: (2016)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
por: Advani, Pooja, et al.
Publicado: (2015)

Luminal B breast tumors are not HER2 positive
por: Bhargava, Rohit, et al.
Publicado: (2008)

HER2 status and disparities in luminal breast cancers
por: Holowatyj, Andreana N., et al.
Publicado: (2016)

Luminal B breast tumors are not HER2 positive – authors' response
por: Tamimi, Rulla M, et al.
Publicado: (2008)

Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas
por: Murase, M, et al.
Publicado: (2009)

Modulation of tumour colony growth by irradiated accessory cells.
por: Hamburger, A. W., et al.
Publicado: (1983)

Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers
por: Hashmi, Atif Ali, et al.
Publicado: (2018)

NEDD9 Overexpression Causes Hyperproliferation of Luminal Cells and Cooperates with HER2 Oncogene in Tumor Initiation: A Novel Prognostic Marker in Breast Cancer
por: Purazo, Marc L., et al.
Publicado: (2023)

High Mutation Burden in ER-Positive/HER2-Negative/Luminal Breast Cancers
por: Voutsadakis, Ioannis A.
Publicado: (2022)

Secretion of transforming growth factors by primary human tumour cells.
por: Hamburger, A. W., et al.
Publicado: (1985)

De novo targeting to the cytoplasmic and luminal side of bacterial microcompartments
por: Lee, Matthew J., et al.
Publicado: (2018)

Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth
por: Patel, J B, et al.
Publicado: (2007)

Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype
por: Yanagawa, Masumi, et al.
Publicado: (2012)

Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes
por: Maisonneuve, Patrick, et al.
Publicado: (2014)

The putative tumour suppressor protein Latexin is secreted by prostate luminal cells and is downregulated in malignancy
por: Seed, Robert I., et al.
Publicado: (2019)

Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer
por: Kang, Byeongju, et al.
Publicado: (2023)

Modulating cancer stemness provides luminal a breast cancer cells with HER2 positive-like features
por: Mei, Yi, et al.
Publicado: (2020)

Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer
por: Alvarez-Lopez, I., et al.
Publicado: (2020)

Spontaneous Epithelial-Mesenchymal Transition and Resistance to HER-2-Targeted Therapies in HER-2-Positive Luminal Breast Cancer
por: Lesniak, David, et al.
Publicado: (2013)

HER-2 overexpression differentially alters transforming growth factor-β responses in luminal versus mesenchymal human breast cancer cells
por: Wilson, Cindy A, et al.
Publicado: (2005)

Cerebellar preference of luminal A and B type and basal ganglial preference of HER2-positive type breast cancer-derived brain metastases
por: Izutsu, Nobuyuki, et al.
Publicado: (2021)

Cytotoxic T-cell precursor frequencies to HER-2 (369 – 377) in patients with HER-2/neu-positive epithelial tumours
por: Sotiropoulou, P A, et al.
Publicado: (2003)

CSPP1 stabilizes growing microtubule ends and damaged lattices from the luminal side
por: van den Berg, Cyntha M., et al.
Publicado: (2023)

EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2(+), basal-like, and HER2 intrinsic subtypes of breast cancer
por: Soysal, S D, et al.
Publicado: (2013)

Side population of a murine mantle cell lymphoma model contains tumour-initiating cells responsible for lymphoma maintenance and dissemination
por: Vega, Francisco, et al.
Publicado: (2010)

Permeability of Luminal Surface of Intestinal Mucosal Cells
por: Lindemann, B., et al.
Publicado: (1962)

Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer
por: Aleskandarany, Mohammed A, et al.
Publicado: (2012)

Induced p53 loss in mouse luminal cells causes clonal expansion and development of mammary tumours
por: Tao, Luwei, et al.
Publicado: (2017)

Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer
por: Park, Soon Young, et al.
Publicado: (2023)

Endocrine Therapy Plus Anti-HER2 Therapy as Adjuvant Systemic Therapy for Luminal HER2-Positive Breast Cancer: An Analysis of the National Cancer Database
por: Nahleh, Zeina A, et al.
Publicado: (2020)

Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
por: Cheang, Maggie C. U., et al.
Publicado: (2009)

The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score
por: Yang, Zheng‐Jun, et al.
Publicado: (2022)

A primary luminal/HER2 negative breast cancer patient with mismatch repair deficiency
por: Yang, Xue, et al.
Publicado: (2023)

CD49f and CD61 identify Her2/neu-induced mammary tumor initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling
por: Lo, Pang-Kuo, et al.
Publicado: (2011)

Luminal Chemosensory Cells in the Small Intestine
por: Burman, Andreanna, et al.
Publicado: (2021)

THE TOTAL LUMINOUS EFFICIENCY OF LUMINOUS BACTERIA
por: Harvey, E. Newton
Publicado: (1925)

Side Population Cells as Prototype of Chemoresistant, Tumor-Initiating Cells
por: Richard, Vinitha, et al.
Publicado: (2013)

Expansion of Luminal Progenitor Cells in the Aging Mouse and Human Prostate
por: Crowell, Preston D., et al.
Publicado: (2019)

On the theory of the "luminous" electrons
por: Sokolov, A A
Publicado: (1956)

Cannot write session to /tmp/vufind_sessions/sess_unrq3mrlh3hhd4vhqgueu6ga3g